Protara Therapeutics Inc (TARA) soared 2.34 in the last month: It’s impossible to believe the numbers

On Tuesday, Protara Therapeutics Inc (NASDAQ: TARA) opened higher 2.34% from the last session, before settling in for the closing price of $3.85. Price fluctuations for TARA have ranged from $1.60 to $10.48 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Company’s average yearly earnings per share was noted 22.27% at the time writing. With a float of $32.88 million, this company’s outstanding shares have now reached $35.04 million.

In an organization with 33 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Protara Therapeutics Inc (TARA) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Protara Therapeutics Inc is 10.58%, while institutional ownership is 79.44%. The most recent insider transaction that took place on Mar 26 ’25, was worth 96,145. In this transaction Chf Scientific Operations Off of this company sold 21,224 shares at a rate of $4.53, taking the stock ownership to the 98,861 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Officer proposed sale 21,224 for $4.55, making the entire transaction worth $96,569.

Protara Therapeutics Inc (TARA) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 22.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.40% during the next five years compared to 55.31% growth over the previous five years of trading.

Protara Therapeutics Inc (NASDAQ: TARA) Trading Performance Indicators

Check out the current performance indicators for Protara Therapeutics Inc (TARA). In the past quarter, the stock posted a quick ratio of 15.71.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -2.07 in one year’s time.

Technical Analysis of Protara Therapeutics Inc (TARA)

Let’s dig in a bit further. During the last 5-days, its volume was 0.56 million. That was better than the volume of 0.31 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 42.54%. Additionally, its Average True Range was 0.32.

During the past 100 days, Protara Therapeutics Inc’s (TARA) raw stochastic average was set at 19.50%, which indicates a significant decrease from 40.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.05% in the past 14 days, which was lower than the 124.47% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.05, while its 200-day Moving Average is $3.30. However, in the short run, Protara Therapeutics Inc’s stock first resistance to watch stands at $4.08. Second resistance stands at $4.22. The third major resistance level sits at $4.37. If the price goes on to break the first support level at $3.79, it is likely to go to the next support level at $3.64. Assuming the price breaks the second support level, the third support level stands at $3.50.

Protara Therapeutics Inc (NASDAQ: TARA) Key Stats

There are currently 36,767K shares outstanding in the company with a market cap of 144.86 million. Presently, the company’s annual sales total 0 K according to its annual income of -44,600 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -12,770 K.